Intraocular Pressure, Safety and Quality of Life in Glaucoma Patients Switching to Latanoprost from Adjunctive and Monotherapy Treatments

Haverkamp, F.; Wuensch, S; Fuchs, Mary Anne; Wc, Stewart

doi:10.1177/112067210401400508

Cited by 25 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data are seemingly inconsistent, however, with those of previous studies which showed switching patients from DTFC to latanoprost also provided a decrease in pressure (Zimmerman & Stewart 2003;Bayer et al 2004;Haverkamp et al 2004;Hamacher et al 2004). The reason why patients would have further reductions in pressure depending on the order in which the medicines were prescribed is not clear, but it may be based on several potential mechanisms: firstly, patients may have a true increase in efficacy with the new medication.…”

Section: Discussioncontrasting

confidence: 53%

“…Trials in the USA and Germany have shown generally that patients on other mono-and adjunctive therapies, including DTFC, experienced a further statistical reduction in IOP when they switched to latanoprost or latanoprost ⁄ timolol fixed combination (Zimmerman & Stewart 2003;Bayer et al 2004;Haverkamp et al 2004;Hamacher et al 2004).…”

Section: Discussionmentioning

confidence: 99%

“…However, in several open-label trials, in which patients on the fixed combination were switched to latanoprost, the prostaglandin analogue was found to be more effective (Zimmerman & Stewart 2003;Bayer et al 2004;Haverkamp et al 2004;Hamacher et al 2004). This design attempted to emulate physician practice by changing therapy, as opposed to assigning medication, as one would in a well controlled, double-masked trial.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy

Sonty

Henry²,

Sharpe

et al. 2008

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Purpose: We aimed to investigate the safety and efficacy of dorzolamide ⁄ timolol fixed combination (DTFC) in timolol responders with ocular hypertension or open-angle glaucoma who switched to DTFC because of insufficient control on latanoprost. Methods:We carried out a prospective, open-label cohort study with an active-historical control in which qualifying patients must have been treated with latanoprost monotherapy for at least 4 weeks, must have demonstrated insufficiently controlled intraocular pressure (IOP) ( ‡ 19 mmHg at 08.00 hours), and must have shown a decrease in IOP at 2 hours after timolol instillation of ‡ 3 mmHg or ‡ 15%. Patients then began DTFC dosed at 08.00 hours and 20.00 hours and discontinued latanoprost. Patients were evaluated again after 4 and 12 weeks.Results: In 57 patients IOP was further reduced by 2.4 ± 3.3 mmHg at 08.00 hours (p < 0.0001) and by 3.5 ± 3.3 mmHg at 10.00 hours (p < 0.0001) after switching to DTFC. Responses to the Comparison of Ophthalmic Medications for Tolerability (COMTol) questionnaire showed no difference between DTFC and latanoprost for in terms of overall preference, typical daily activities, limitation of activities, compliance, satisfaction or quality of life (p > 0.05). However, greater frequency in burning and ⁄ or stinging (p < 0.0001) and bitter taste (p < 0.0001) were observed with DTFC, whereas unusual taste (p = 0.02) and itchy eyes (p = 0.05) were associated with latanoprost.Conclusions: This study suggests that patients who are insufficiently controlled on latanoprost monotherapy, and who are timolol responders, can generally achieve further IOP reduction and similar tolerance levels when changed to DTFC.

show abstract

Section: Discussioncontrasting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy

Sonty

Henry²,

Sharpe

et al. 2008

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…1 Long-term use of topical ocular drugs is often associated with ocular inflammation, allergy, dry eye syndrome, and failure of filtration surgery. [2][3][4][5][6][7][8] Several lines of evidence indicate that these agents are associated with decreased tear turnover and tear film break-up time, infiltration of the conjunctiva by inflammatory cells and fibroblasts, and overexpression of inflammatory markers such as HLA-DR, intercellular adhesion molecule (ICAM-1), FAS antigen, or the apoptotic marker Apo 2.7. 9 -14 The preservative benzalkonium chloride (BAK), the most commonly used ocular preservative, is largely responsible for the ocular toxicities and inflammation associated with the chronic use of many ophthalmic solutions.…”

mentioning

confidence: 99%

In Vitro Studies of Antiglaucomatous Prostaglandin Analogues: Travoprost with and without Benzalkonium Chloride and Preserved Latanoprost

Baudouin

Riancho

Warnet

et al. 2007

Invest. Ophthalmol. Vis. Sci.

104

View full text Add to dashboard Cite

show abstract

“…periocular dermatitis -as Baudouin refers, 20 in addition to allergic conjunctivitis, (which rarely corresponds to type i hypersensitivity) the most frequent drug-induced allergic reaction is a type iV delayed cell-mediated hypersensitivity. this could explain why many reactions occur at the eyelid level, (such as allergic blepharitis) which are often difficult to distinguish from other causes of eyelid inflammation or contact dermatitis (see Figure 3).…”

Section: Preservatives and Effectsmentioning

confidence: 99%

Ocular Surface Morbidities in Glaucoma

Benítez-del-Castillo¹,

Cantu-Dibildox²,

Galbis-Estrada³

et al. 2013

European Ophthalmic Review

View full text Add to dashboard Cite

Introduction: ocular surface disease (oSd) is a major cause of ophthalmological consultation. Within this group, glaucoma patients constitute an important percentage due to the nature of their chronic topical treatment. advances in the understanding of ocular surface pathology on both a cellular and molecular level, and the interaction to the toxic nature of some topical medication solution compounds, are stimulating the development of better alternatives in topical treatment. Materials and Methods: Extensive review of available literature and current research on topical ophthalmological treatments in both oSd and glaucoma was performed. Emphasis was made on inflammatory modulators of the ocular surface and pathological changes associated with the use of preservatives in solutions, in particular benzalkonium chloride (BaK). independent research is been also performed by the authors, using a rubbing-induced reflex tears collecting method with capillary tubes. cytokines in tear samples were subsequently analysed with the multi-Plex System (luminex ® R-200). The 12 cytokines analysed using this method are the interleukins (il)-1β, il-2, il-4, il-5, il-6, il-7, il-8, il-10, il-12, the tumour necrosis factor alpha (TNFα), the vascular endothelial growth factor (VEGF), the granulocyte-macrophage-colony stimulating factor (GM-cSF) and the interferon gamma (iFg). Results: our unpublished, preliminary results trend to show higher values in il-5 and il-6 in glaucoma patients than in normal controls. also, higher values in il-2, il-5 and il-12 in dry eye syndrome (dES) patients were found versus normal controls. Conclusions: inflammation is an important element in oSd and strong association seems to exist between this and the use of BaK preservative. New kinds of preservative molecules, as well as single-dose eye drops and sophisticated dispensing bottle mechanisms, are currently available on the market in order to avoid the secondary effects of this topical treatments, increasing patient compliance and adherence to chronic topical glaucoma treatment.

show abstract

Intraocular Pressure, Safety and Quality of Life in Glaucoma Patients Switching to Latanoprost from Adjunctive and Monotherapy Treatments

Abstract: In a clinical setting, patients who have their mono- and adjunctive therapy treatment substituted for latanoprost may on average experience reduced IOP, decreased side effects and increased quality of life measures.

Cited by 25 publications

References 14 publications

Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy

Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy

In Vitro Studies of Antiglaucomatous Prostaglandin Analogues: Travoprost with and without Benzalkonium Chloride and Preserved Latanoprost

Ocular Surface Morbidities in Glaucoma

Contact Info

Product

Resources

About